Patient Information Website
Click here to access
LUVOX CR information for
patients.
Prescribing Information
Download the full
prescribing information.
Upcoming Conventions
Below is a listing of some upcoming mental health conventions and conferences.
These websites and conferences are listed for the benefit of those that may be interested in them. This site does not promote any of the websites or conferences listed.
15th Annual Obsessive Compulsive Foundation Conference
The Annual OCF Conference is the meeting where people from all parts of the OCD Community come together to share knowledge, experience and expertise. The OCD Community is composed of people with OCD or an OC spectrum disorder, their families and friends and the mental health professionals who treat OCD or are doing research in the field.
Date: August 1–3, 2008
Location: Boston, MA
U.S. Psychiatric and Mental Health Congress
U.S. Psychiatric and Mental Health Congress was designed to meet the continuing education needs of psychiatrists and other physicians, physician assistants, pharmacists, psychologists, registered nurses, advanced practice nurses, advanced practice psychiatric nurses, and licensed social workers and counselors.
Date: October 30–November 2, 2008
Location: San Diego Convention Center and Marriott Hotel & Marina
Anxiety Disorders Association of America 2009 Annual Conference
Anxiety and Comorbid Disorders: Understanding Risk, Optimizing Outcomes
Date: March 12–15, 2009
Location: Hyatt Regency Tamaya, New Mexico
APA Convention 2009
The American Psychological Association's 117th annual convention
Date: May 16–21, 2009
Location: San Francisco, CA
Once-A-Day LUVOX CR® (fluvoxamine maleate) Extended-Release Capsules are indicated for the treatment of social anxiety disorder (SAD) and obsessive compulsive disorder (OCD).
Important Safety Information
CONTRAINDICATIONS
The use of alosetron, tizanidine, thioridazine, or pimozide with LUVOX CR Capsules is contraindicated. The use of MAO inhibitors in combination with LUVOX CR Capsules, or within 14 days of discontinuing treatment with LUVOX CR Capsules, is contraindicated (see WARNINGS and PRECAUTIONS). LUVOX CR Capsules are also contraindicated in patients with a history of hypersensitivity to fluvoxamine maleate or any of its excipients.
ADVERSE EVENTS
In clinical trials, the most commonly observed adverse events with an incidence of ≥5% and at least twice that of placebo were nausea, somnolence, asthenia, diarrhea, anorexia, tremor, and sweating. Overall, these side effects were mild to moderate in severity and transient in nature. Other common adverse events (≥5% and at least twice that of placebo) included abnormal ejaculation and anorgasmia.
Suicidality and Antidepressant Drugs
Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of LUVOX CR® (fluvoxamine maleate) Extended-Release Capsules or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. LUVOX CR Capsules are not approved for use in pediatric patients. (See WARNINGS: Clinical Worsening and Suicide Risk, PRECAUTIONS: Information for Patients, and PRECAUTIONS: Pediatric Use.)
Please see full prescribing information, including boxed warning, for LUVOX CR.
LUVOX CR is a registered trademark of Solvay Pharmaceuticals, Inc.
© 2008 Jazz Pharmaceuticals, Inc.
